FAQ

NOV 002

Known as: NOV-002, NOV002, Oxidized Glutathione NOV-002 
A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2015
012320052015

Related topics

Related topics

3 relations

Broader (3)

CisplatinDrug CombinationsGlutathione Disulfide

Related mentions per year

Related mentions per year

1943-2018
19401960198020002020
NOV 002
Cisplatin
Drug Combinations
Glutathione Disulfide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis
Metastasis is the major cause of death in cancer. Most therapies currently in the clinic aim to eradicate primary tumor, but do… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.
The oxidized glutathione mimetic NOV-002 is a unique anti-tumor agent that not only has the ability to inhibit tumor cell… (More)
Is this relevant?
2011
2011
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer
NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic.
NOV-002 is a glutathione disulfide (GSSG) mimetic that is the subject of clinical investigation in oncology indications. GSSG is… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • table 2
Is this relevant?
2010
2010
Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity.
NOV-002 is a glutathione disulfide (GSSG) mimetic with chemoprotective activity. Previous and ongoing clinical studies… (More)
Is this relevant?
2009
2009
Pharmacology of a mimetic of glutathione disulfide, NOV-002.
NOV-002 is a novel therapeutic agent in development for oncology indications used in combination with chemotherapy. Clinical… (More)
Is this relevant?
2008
2008
NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance.
NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Cellular Redox Balance NOV-002, a Glutathione Disulfide Mimetic, as a Modulator of Updated Version
NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
2008
Review
2008
NOV-002, a mimetic of glutathione disulfide.
BACKGROUND Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new… (More)
Is this relevant?
2006
2006
NOV-002, a chemoprotectant/immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): A randomized Phase 1/2, open-label, controlled study.
17021 Background: NOV-002 is a proprietary formulation of oxidized glutathione that modulates production of cytokines and… (More)
Is this relevant?